[
  {
    "ts": null,
    "headline": "Why The Narrative Around Moderna (MRNA) Is Shifting After Mixed Analyst Updates",
    "summary": "What Is Driving the Updated Fair Value for Moderna? Analyst models on Moderna have been refreshed, with the fair value estimate moving from US$36.75 to US$38.80 and the discount rate adjusting slightly from 7.11% to about 7.09%, alongside a higher assumed long term revenue growth rate, now around 11.47% instead of roughly 10.37%. These changes reflect how recent research is weighing better visibility on long term revenue potential against ongoing execution and pipeline risks, while still...",
    "url": "https://finnhub.io/api/news?id=cdd380bf26f00df47793d9abc9c98d0914ae93f12bddd89984c367a5aa2468ba",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770138790,
      "headline": "Why The Narrative Around Moderna (MRNA) Is Shifting After Mixed Analyst Updates",
      "id": 138344163,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "What Is Driving the Updated Fair Value for Moderna? Analyst models on Moderna have been refreshed, with the fair value estimate moving from US$36.75 to US$38.80 and the discount rate adjusting slightly from 7.11% to about 7.09%, alongside a higher assumed long term revenue growth rate, now around 11.47% instead of roughly 10.37%. These changes reflect how recent research is weighing better visibility on long term revenue potential against ongoing execution and pipeline risks, while still...",
      "url": "https://finnhub.io/api/news?id=cdd380bf26f00df47793d9abc9c98d0914ae93f12bddd89984c367a5aa2468ba"
    }
  },
  {
    "ts": null,
    "headline": "Moderna Refocuses On Rare Disease Pipeline As Leadership Evolves",
    "summary": "Moderna (NasdaqGS:MRNA) announced a collaboration with Recordati to develop and commercialize mRNA-3927 for propionic acidemia, a rare metabolic disorder. The company also confirmed leadership changes, including the appointment of David Berman as Chief Development Officer and the planned departure of Chief Medical Officer Jacqueline Miller. These updates come as Moderna expands its mRNA pipeline beyond COVID-19 vaccines into rare diseases and other therapeutic areas. For you as an investor,...",
    "url": "https://finnhub.io/api/news?id=6db15080187d0a94bcbdad9183c0af71cb0f81725790a9b0762123b4501c4bec",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770135062,
      "headline": "Moderna Refocuses On Rare Disease Pipeline As Leadership Evolves",
      "id": 138344499,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Moderna (NasdaqGS:MRNA) announced a collaboration with Recordati to develop and commercialize mRNA-3927 for propionic acidemia, a rare metabolic disorder. The company also confirmed leadership changes, including the appointment of David Berman as Chief Development Officer and the planned departure of Chief Medical Officer Jacqueline Miller. These updates come as Moderna expands its mRNA pipeline beyond COVID-19 vaccines into rare diseases and other therapeutic areas. For you as an investor,...",
      "url": "https://finnhub.io/api/news?id=6db15080187d0a94bcbdad9183c0af71cb0f81725790a9b0762123b4501c4bec"
    }
  },
  {
    "ts": null,
    "headline": "Are Wall Street Analysts Bullish on Moderna Stock?",
    "summary": "While Moderna has outpaced the S&P 500 over the past year, Wall Street analysts maintain a cautious outlook about the stock’s prospects.",
    "url": "https://finnhub.io/api/news?id=f2a3b349b4e897cda602d23e9882ef50603c91c6d5f37e28e0dc7c43d6eb4610",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770133069,
      "headline": "Are Wall Street Analysts Bullish on Moderna Stock?",
      "id": 138345618,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "While Moderna has outpaced the S&P 500 over the past year, Wall Street analysts maintain a cautious outlook about the stock’s prospects.",
      "url": "https://finnhub.io/api/news?id=f2a3b349b4e897cda602d23e9882ef50603c91c6d5f37e28e0dc7c43d6eb4610"
    }
  },
  {
    "ts": null,
    "headline": "These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar",
    "summary": "Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.",
    "url": "https://finnhub.io/api/news?id=b4f731442c9957465e63b34ce5c8a288fa33a9a36a2f6f6c6ff9dad64e20b94d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770127205,
      "headline": "These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar",
      "id": 138342967,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.",
      "url": "https://finnhub.io/api/news?id=b4f731442c9957465e63b34ce5c8a288fa33a9a36a2f6f6c6ff9dad64e20b94d"
    }
  },
  {
    "ts": null,
    "headline": "CRSP to Report Q4 Earnings: Is a Beat in Store for the Stock?",
    "summary": "CRISPR Therapeutics heads into Q4 earnings with rising Casgevy sales, collaboration revenues from Vertex, and a history of beating estimates.",
    "url": "https://finnhub.io/api/news?id=048ef9c6933d20140786663c8c565fe02b1ca1e1b7360358b901c285086dc586",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770125400,
      "headline": "CRSP to Report Q4 Earnings: Is a Beat in Store for the Stock?",
      "id": 138342700,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "CRISPR Therapeutics heads into Q4 earnings with rising Casgevy sales, collaboration revenues from Vertex, and a history of beating estimates.",
      "url": "https://finnhub.io/api/news?id=048ef9c6933d20140786663c8c565fe02b1ca1e1b7360358b901c285086dc586"
    }
  },
  {
    "ts": null,
    "headline": "How Moderna Uses Decision Intelligence to Enable an Autonomous Cold Chain, Upcoming Webinar Hosted by Xtalks",
    "summary": "Cold chain logistics within pharmaceutical supply chains are undergoing a fundamental transformation as organizations confront rising product complexity, expanding global networks and mounting pressure to reduce waste, cost and manual intervention. Join this webinar to learn about Moderna's evolving blueprint for enabling an autonomous cold chain, highlighting how blind spot elimination, data consolidation and decision intelligence can unlock meaningful operational change.",
    "url": "https://finnhub.io/api/news?id=39ba3e7d474bd537cbc82b36b4ece0b5813f07053f60429705f72bd080f7de66",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770125400,
      "headline": "How Moderna Uses Decision Intelligence to Enable an Autonomous Cold Chain, Upcoming Webinar Hosted by Xtalks",
      "id": 138341934,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Cold chain logistics within pharmaceutical supply chains are undergoing a fundamental transformation as organizations confront rising product complexity, expanding global networks and mounting pressure to reduce waste, cost and manual intervention. Join this webinar to learn about Moderna's evolving blueprint for enabling an autonomous cold chain, highlighting how blind spot elimination, data consolidation and decision intelligence can unlock meaningful operational change.",
      "url": "https://finnhub.io/api/news?id=39ba3e7d474bd537cbc82b36b4ece0b5813f07053f60429705f72bd080f7de66"
    }
  },
  {
    "ts": null,
    "headline": "New Drugs Take Center Stage as Biogen Heads Into Q4 Earnings",
    "summary": "Biogen heads into Q4 earnings with MS drug pressure, while Leqembi and Skyclarys' growth could help offset declines ahead of its Feb. 6 report.",
    "url": "https://finnhub.io/api/news?id=97013c3399ae4454f60a2ef7629b331ac983fee8d6b0dcd7c332d70683a53752",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770123360,
      "headline": "New Drugs Take Center Stage as Biogen Heads Into Q4 Earnings",
      "id": 138342021,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Biogen heads into Q4 earnings with MS drug pressure, while Leqembi and Skyclarys' growth could help offset declines ahead of its Feb. 6 report.",
      "url": "https://finnhub.io/api/news?id=97013c3399ae4454f60a2ef7629b331ac983fee8d6b0dcd7c332d70683a53752"
    }
  },
  {
    "ts": null,
    "headline": "Arbutus Biopharma: LNP Litigation And Imdusiran Drive Near-Term Catalysts",
    "summary": "Arbutus Biopharma: LNP Litigation And Imdusiran Drive Near-Term Catalysts",
    "url": "https://finnhub.io/api/news?id=928024464a0cf2f07d46a2a99bd9e8f695faa6f9bf7d61f0208ccc5ae3ed78b1",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770104884,
      "headline": "Arbutus Biopharma: LNP Litigation And Imdusiran Drive Near-Term Catalysts",
      "id": 138341226,
      "image": "",
      "related": "MRNA",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=928024464a0cf2f07d46a2a99bd9e8f695faa6f9bf7d61f0208ccc5ae3ed78b1"
    }
  }
]